Evidence map›Paper›PMID 40217384›Full record

ArticleActa epileptologica2025

MDN1 variants cause susceptibility to epilepsy : For the China Epilepsy Gene 1.0 Project.

Qianru Wen, Dongming Zhang, Yan Ding, Sheng Luo, Qiang Huang, Junhui Zhu, Yongxin Li, Wenhui Liu, Pengyu Wang, Xian Li and 6 more

Abstract read
In one paragraph

Article in Acta epileptologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Qianru Wen *Department of Neurology, The Sixth Affiliated Hospital of Jinan University, Dongguan, 523573, China.
Dongming Zhang *Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Yan Ding *Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Sheng LuoDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Qiang HuangDepartment of Pediatric, Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital, Jishou, 416000, China.
Junhui ZhuDepartment of Neurology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518000, China.
Yongxin LiDepartment of Neurology, Shunde Hospital of Southern Medical University (the First Hospital of Shunde), Shunde, 528308, China.
Wenhui LiuDepartment of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Pengyu WangDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Xian LiDepartment of Pediatric, Zhuhai Women'S and Children'S Hospital, Zhuhai, 519000, China.
Zisheng LinDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Yaying WangDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Xiaoyu LiangDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Weiping LiaoDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Jie WangDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China. wangjie2014010@163.com.
Heng MengDepartment of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China. memphisheng@163.com.ORCID http://orcid.org/0000-0002-8859-6042

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515010218City School (institute) Enterprise Joint Funding Project of Guangzhou Science and Technology Bureau 2025A03J4094Dongguan Science and Technology Bureau 20231800905272Fundamental Research Funds for the Central Universities 21623405Medical Joint Fund of Jinan University YXJC2022010Science and Technology Projects in Guangzhou 2023A03J1026
6 · The paper itself

Abstract

backgroundThe Midasin AAA (ATPase associated with various activities) ATPase 1 (MDN1) gene, a member of the AAA protein family, plays a crucial role in ribosome maturation. MDN1 is expressed in the human brain throughout life, especially during early development and adulthood. However, MDN1 variants have not been previously reported in patients with epilepsy. This study aims to explore the association between MDN1 variants and epilepsy.

methodsTrios-based whole-exome sequencing was performed in a cohort of patients with epilepsy susceptibility from the China Epilepsy Gene 1.0 Project. The excess, damaging effects, and molecular subregional implications of variants, as well as the spatio-temporal expression of MDN1, were analyzed to validate the gene-disease association.

resultsCompound heterozygous variants in MDN1 were identified in five unrelated patients with febrile seizures or secondary epilepsy. Three patients presented with febrile seizures/epilepsy with febrile seizures plus, while two patients developed epilepsy secondary to brain damage (five or seven years after). These variants were either absent or present at low frequencies in the control group, and exhibited statistically significant higher frequencies in the case group compared to controls. All the missense variants were predicted to be damaging by at least one in silico tool. In each pair of compound heterozygous variants, one allele was located in the AAA2-AAA3 domains, while the other allele was located in the linker domain or its vicinity. In contrast, most of the variants from the asymptomatic control group were located outside the AAA domains, suggesting a molecular subregional implication of the MDN1 variants.

conclusionsMDN1 is potentially a susceptibility gene for epilepsy.

Indexed as

Brain damageEpilepsyFebrile seizuresMDN1 variantsMolecular subregional implicationSusceptibility

Identifiers

PMID40217384
PMCPMC11960335

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.